Overview

Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer